Arvinas, Inc. Aktie News

NEW HAVEN, Conn., 01. Sept. 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) („Arvinas" oder das „Company"), ein im klinischen Stadium befindliches Biotechnologieunternehmen, das eine neue Wirkstoffklasse auf Basis des gezielten Proteinabbaus entwickelt, gab heute bekannt, dass das Company 45.696 Restricted Stock Units („RSU") an einen neu eingestellten Mitarbeiter (die „RSU Award") gewähr...

– Erzielt die weltweit erste behördliche Zulassung eines PROTAC (einer Art heterobifunktionaler Protein‑Degrader), VEPPANU, und schloss erfolgreich eine Auslizenzierung an Rigel Pharmaceuticals ab – – Erwartet die Veröffentlichung klinischer Daten aus drei Phase‑1‑Programmen – ARV‑393, ARV‑102 und ARV‑027 – innerhalb der nächsten 12 Monate – – Präsentierte vielversprechende präklinische Daten f...

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of ...

Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights to VEPPANU – – Presented ARV-102 (LRRK2 degrader) Phase 1 clinical data in patients with Parkinson...